Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) shares hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $129.35 and last traded at $129.35, with a volume of 908 shares changing hands. The stock had previously closed at $124.45.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. BTIG Research began coverage on Zealand Pharma A/S in a research report on Thursday, March 7th. They issued a “buy” rating for the company. Cantor Fitzgerald assumed coverage on shares of Zealand Pharma A/S in a report on Tuesday, May 21st. They set an “overweight” rating for the company.
View Our Latest Analysis on ZLDPF
Zealand Pharma A/S Stock Performance
Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.54) EPS for the quarter. The firm had revenue of $2.20 million during the quarter. Zealand Pharma A/S had a negative net margin of 213.77% and a negative return on equity of 36.96%. Analysts forecast that Zealand Pharma A/S will post -2.54 earnings per share for the current year.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Read More
- Five stocks we like better than Zealand Pharma A/S
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What is the Australian Securities Exchange (ASX)
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.